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Abstract
Background: Various types of markers have been used so far in order to reveal myocardial perfusion defect.
However, these markers usually appear in the necrosis phase or in the late stage. Having been the focus of various
investigations recently, ischemia-modified albumin (IMA) is helpful in establishing diagnosis in the early stages of
ischemia, before necrosis develops.
Methods and Results: 30 patients that underwent only coronary bypass surgery due to ischemic heart disease
within a specific period of time have been included in the study. IMA levels were studied in the preoperative,
intraoperative, and postoperative periods. The albumin cobalt binding assay was used for IMA determination.
Hemodynamic parameters (atrial fibrillation, the need for inotropic support, ventricular arrhythmia) of the patients
in the postoperative stage were evaluated. Intraoperative measurement values (mean ± SD) of IMA (0.67677 ±
0.09985) were statistically significantly higher than those in the preoperative (0.81516 ± 0.08894) and postoperative
(0.70477 ± 0.07523) measurements. Considering atrial fibrillation and need for inotropics, a parallelism was detected
with the levels of IMA.
Conclusions: IMA is an early-rising marker of cardiac ischemia and enables providing a direction for the treatment
at early phases.
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Background
Recent studies show that the structure of serum albu-
min changes when ischemia develops in the body. From
this point of view, studies focusing on a new marker for
myocardial ischemia have been carried out. Ischemia
Modified Albumin is a new marker used to detect myo-
cardial ischemia and it shows an early change [1,2]. Ele-
vations in IMA levels have been detected following
percutaneous coronary interventions [3,4]. It is also used
for differential diagnosis in patients admitting to emer-
gency departments with angina pectoris [5]. It has
recently been reported that IMA also increases in case
of pulmonary infarction, critical limb ischemia, cerebro-
vascular disease conditions [6-10].
Ischemia-modified albumin (IMA), a Food and Drug
Administration-approved serum biomarker of cardiac
ischemia and a risk stratification tool for suspected
acute coronary syndrome, is produced during an
ischemic condition or attack and is present in the blood
in early and easily detectable levels [5,11]. The increase
in markers that predict myocyte necrosis during or after
CABG surgery usually parallels with a poor prognosis of
the patient. Numerous markers have been used to reveal
myocardial necrosis until today [12,13]. These markers
have been used as diagnostic criteria for myocardial
necrosis that develops after CABG operations [14]. IMA
is a marker formed after damage in the N terminal
region of the albumin in ischemic conditions. Endothe-
lial or extracellular hypoxia, acidosis, and free oxygen
radicals have been shown to cause IMA increase [15]. In
this study, we have intended to determine the associa-
tion between IMA levels and hemodynamic parameters
of the patients.
Materials and methods
The study was planned upon obtaining approval from
the ethics board of our hospital. 30 patients, on which
merely CABG was to be performed within a certain
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time frame, were included in the study. Patients who
required concurrent valve or another cardiac interven-
tion were not included in the study. Patients with ser-
ious liver, kidney, peripheral vascular, or cerebral
pathologies were also excluded from the study.
Surgical procedure
Anesthetic management was uniform in all patients.
Midazolam was used for premedication, and a combina-
tion of fentanyl, midazolam and pancuronium was used
for the induction. After intubation, mechanical ventila-
tion with oxygen and nitrogen was initiated. Anesthesia
was maintained with midazolam, vecuronium bromide
and inhaled sevoflurane. Patients were all operated on
by the same surgical team. CABG was performed with
moderate hypothermia. After the aorta was cross-
clamped and 1000 mL of high-potassium cold-blood
cardioplegic solution (24° to 26°C) (10-15 mL/kg) was
perfused one time in an antegrade, myocardial revascu-
larization was performed during cardioplegic arrest at
28°C to 30°C. The cardioplegic solution was composed
of whole blood with a hemoglobin level of 8 g/dL and
25 mEq/L KCl. Following antegrade cardioplegia, cardio-
plegia solution containing 10 mEq/L KCl was constantly
administered via retrograde path through the coronary
sinus. Distal anastomoses were made. Proximal anasto-
moses were performed under side clamping. Following
the completion of the surgery, the patients were taken
to intensive care. Standard postoperative care was given
to all the patients. Extubation was performed at the ear-
liest stage possible following the provision of hemody-
namic stability. The first choice when inotropic agent
requirement emerged was dopamine. At times when
atrial fibrillation occurred, amiodarone was the first
choice for treatment in case laboratory and blood gas
values were normal.
Biochemical assays
Blood samples were drawn from the coronary sinus
right before cross-clamping and 30 minutes after cross-
clamping. Six hours after the operation, other blood
samples were taken from a central venous catheter,
which was forwarded into the right atrium and the IMA
levels were studied. The blood samples were placed in
flat tubes and kept waiting for 30 minutes, then sera
were separated by centrifuging at 3000 rpm for 10 min-
utes. Then the obtained serum samples were subjected
to measurement immediately. Albumin Cobalt binding
test was analyzed according to the method defined by
Bar-Or et al. [16]. In this method 200 mL serum was
added to the water solution of 50 mL %0, 1 (w/v) cobalt
chloridine (sigma;CoCl2.6H2O). It was mixed gently and
waited for 10 minutes for sufficient cobalt-albumin
binding. Then 50 mL dithiothreitol (DTT) (Sigma 1.5
mg/mL H2O) was added as a colorizing agent. After
waiting for two minutes 1.0 mL 0.9% NaCl was added
to stop the cobalt binding process of albumin. After-
wards, the absorbance was measured through spectro-
photometer at 470 nm (Shimadzu, model UV160U).
Sample blank without DTT were used as blind. The
results were reported as absorbance units (ABSU).
Statistical Analysis
The analyses were performed using SPSS for Windows,
version 13.0. Normal distribution test was applied. Due
to its preoperative variable that does not confirm to
normal distribution, non-parametric tests were per-
formed in comparisons containing the preoperative vari-
able. Based on the normal distribution analysis of data,
the Friedman test, Wilcoxon Signed Rank test and
Paired sample t test were used in the comparisons of
the dependent groups, while independent group com-
parisons were conducted using the Mann-Whitney U
test. The level of statistical significance was taken as p <
0.05 and the Bonferroni correction was used where
needed.
Results
22 of the patients were males while 8 were females. The
mean age of the patients was 58,6 (39 to 79). The demo-
graphics characteristics of the patients are given in the
Table 1. In the echocardiograms of the cases, the ejec-
tion fractions were 35% and below in 12 cases (40%);
between 36% and 50% in 7 cases (23%) and above 51%
in 11 cases (37%). Single-vessel bypass surgery in one
case, 2-vessel bypass surgery in another case, 3-vessel
bypass surgery in 11 cases, 4-vessel bypass surgery in 14
Table 1 Demographics characteristics of the cases
%
Age (years) 58,6
Male, n (%) 22 -73%
Diabetes Mellitus, n 11 -36%
Hypertension, n 15 -50%
Smoking, n 17 -56%
Ejection Fraction, n 12 cases 35 > -40%
7 cases 36-50 -23%
11 cases 51 < -37%
Cardiopulmoner bypass time(Mean) 81 min.
Cross clamp time(Mean) 37 min.
Number of bypass vessel, n CABG x1...1 -3%




LIMA graft use, n 27 -90%
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cases, and 5-vessel bypass surgery in 3 cases were per-
formed. LIMA was used as a graft for LAD bypass in a
total of 27 cases. For other vessel bypasses, Vena
saphena magna (the great saphenous vein) was used.
One (3%) of the cases died. The mean cardiopulmonary
bypass duration was 81 minutes and the mean cross-
clamping duration was 37 minutes. In 23 (76%) patients,
a need for a cardiotonic occurred while two (7%) cases
required intra-aortic balloon. Cases in whom intra aortic
balloon was needed were urgent patients who were
taken to bypass surgery in a hemodynamically unstable
condition. Arrhythmias not requiring treatment devel-
oped in 11 (36%) of the cases in the postoperative per-
iod. Paroxysmal AF attacks developed in 16 (53%) cases
during the postoperative period and 6 of these cases
needed treatment for more than 72 hours. All the cases
were discharged from the hospital with sinusoidal
rhythm. Preoperative, peroperative, and postoperative
changes in IMA of the patients were compared, and it
was observed that these changes were significantly dif-
ferent from each other (Friedman test, p < 0.05). Post-
operative IMA measurement values were higher than
those of preoperative IMA. There was a statistically sig-
nificant difference between the preoperative and post-
operative measurements (p = 0.011) (Wilcoxon signed
rank test). In terms of preoperative IMA measurements
and intraoperative measurements, the IMA levels at the
intraoperative stage were higher. The difference between
these values were statistically significant (p < 0.001)
(Wilcoxon signed rank test). When comparing the
intraoperative and postoperative measurements of IMA,
intraoperative phase levels were higher again and the
difference between them was statistically significant (p =
0.001) (Paired sample t test) (Figure 1). Arrhythmias not
requiring treatment developed in 11 (36%) of the cases
in the postoperative period. Paroxysmal AF attacks
developed in 16 (53%) cases during the postoperative
period and 6 of these cases needed treatment for more
than 72 hours. All the cases were discharged from the
hospital with sinusoidal rhythm. 23 (76%) of the cases
required an inotropic (7-15 microgram/kg/min dopa-
mine). The need for an inotropic disappeared in five of
the cases within 6 hours. However, 15 of these cases
needed an inotropic support of 10 mcg/kg/min for 24
hours and more. In two (7%) cases taken to surgery in
emergency settings and with intra-aortic balloon support
and in one case with a low ejection fraction, there was a
need for combined inotropics (dopamine, dobutamine,
adrenaline, and noradrenaline). This support was
required for at least 72 hours. Mortality occurred in one
(3%) case and this was a patient who was taken into an
emergency bypass operation. When the relationship
between the changes in hemodynamic parameters and
IMA changes in the patients was examined, no statistical
significance was identified (Mann-Whitney U, p > 0.05).
Discussion
Myocardial ischemia in various degrees may develop
during the intraoperative phase due to such reasons as
manipulation of the heart, inadequate myocardial pro-
tection, and incomplete revascularization. In order to
reveal myocardial perfusion defect, such markers as
AST, myoglobin, myocardial creatine kinase isoenzymes,
and troponin have been used until today [12,17,18].
Recent studies show that the structure of serum albu-
min changes when ischemia develops in the body. Nor-
mal human albumin has the N terminal region, which
detoxifies free oxygen radicals. The N region is also the
area to which such transition metals as cobalt, copper
and nickel are bound. In the ischemia condition, the N
region is damaged by oxygen radicals. Albumin’s capa-
city to bind metals such as nickel, cobalt and copper is
diminished [7,14,19]. The resultant albumin as such is
IMA. The type of the radical that affects the N terminal
region most is the hydroxyl radical. Free radical binding
capacity of IMA is very low. Elevation of IMA is directly
associated with free radicals that form during ischemia
[20]. IMA is also one of the markers of oxidative stress
[21,22]. Reperfusion after ischemic conditions includes
more free radical and iron and copper exposure, which
may cause even more alterations to albumin than ische-
mia itself [23,24]. In studies conducted in earlier years,
it was shown that IMA levels elevate in cardiac ische-
mia, cerebrovascular occlusion, pulmonary ischemia,
gastrointestinal ischemia, and muscle ischemia
[3,7,8,19,25-27].
A study conducted to scrutinize IMA specifies that
IMA elevation may occur due to coronary vasospasm
[5]. In other words, while the other markers for cardiac
ischemia necessitate necrosis formation, IMA is elevated
even in the early stages of ischemia. The most important
Figure 1 Changes in all measurements of the cases.
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characteristic that differentiates IMA from other cardiac
ischemia markers is that it increases in the early phase
particularly. It elevates in just minutes, peaks within 2
to 4 hours and returns to normal in 6 to 12 hours
[3,28]. Non-existence of myocardial ischemia is consid-
ered to be confirmed in 90-95% of the cases if IMA
levels are normal in the presence of a normal ECG and
normal troponin levels [5]. Rapid elevation of IMA in
minutes could render it usable in patient follow up and
for taking necessary precautions rather earlier.
In this study, we examined the effects of coronary
bypass operations on IMA levels and linkage of these
levels with hemodynamic parameters. It was determined
in a previous study that IMA levels increased shortly
after the operation and decreased later on. However, it
was stated that the amount of this decrease was still
higher than basal levels [29]. In our study, we found
that IMA levels elevated rapidly in the first 30 minutes
following cross-clamping and decreased during the post-
operative 6-hour-phase. However, the amount of this
decrease did not reach to the level of the preoperative
values. We believe that this can be attributed to a tem-
porary effect created by reperfusion. In our study, IMA
levels in the samples taken during the intraoperative
stage were statistically higher than those obtained in the
preoperative and postoperative periods.
Atrial fibrillation is observed in 7 to 40% of the cases
after coronary bypass surgery [30,31]. Paroxysmal AF
attacks emerged in 53% of our cases. The rate of atrial
fibrillation that necessitated treatment for more than 72
hours was 20%.
One of the major factors that determines the need for
inotropics during the postoperative period is the dura-
tion of cross-clamping. If the duration of cross-clamping
is longer than 90 minutes, the need for inotropics
increases [31]. In 23 (76%) of our cases, a need for an
inotropic (7-15 microgram/kg/min dopamine) devel-
oped. Inotropic support of 10 mcg/kg/min for 24 hours
and more became necessary in 15 (50%) of the cases
that required an inotropic. Arrhythmia that did not
require any need for treatment developed in 11 (36%) of
the cases in the postoperative period. When the cases
with prolonged inotropic need as well as the cases with
atrial fibrillation who needed treatment for more than
72 hours (6 cases) were examined, it was understood
that the postoperative IMA levels in these patients
remained higher than the rest of the cases. Although
intraoperative IMA levels were statistically significantly
higher in all cases, it was found that especially in some
cases, arrhythmias lasted longer and more need for ino-
tropics was present. This finding may imply a suspected
presence of a subgroup specific to myocardium. Ventri-
cular arrhythmia, atrial fibrillation, and inotropic
requirement were found to be more in patients whose
IMA values were measured higher. While this excess
was not statistically significant, it was proportionally
higher (in terms of the % value). It might be possible to
attain statistical significance by increasing the number
of the patients. Comparing with the preoperative stage,
IMA levels were elevated more in samples taken 6
hours after the operation. The reason for this could be a
temporary ischemic condition caused by reperfusion.
We believe that these levels would come closer to basal
values in the samples to be taken in the upcoming
hours. The most important factor that restricts the use
of IMA is that it is not a specific marker for myocar-
dium. That being said, IMA may increase in some con-
ditions (septic shock, renal failure, neoplasia, etc.) [32].
Conclusion
Many further studies are required in order to determine
the role of IMA in ischemic conditions that occur in
various organs. Sensitivity of cells to ischemia varies
from one organ to another. It is important to know the
optimal IMA levels to diagnose ischemia particularly in
organs such as the heart and brain. Increasing the num-
ber of the cases and lengthening measurement periods
in these types of studies might help establish this opti-
mal level. IMA is one of the markers that show myocar-
dial ischemia earliest. There is a parallel association
between IMA levels and hemodynamic parameters of
the patients. The most important factor that restricts
IMA is that IMA may elevate in other pathologies as
well, which brings about a requirement for subgroup
studies. Since IMA is an early marker, measurement of
IMA levels may contribute to patient follow up and
initiation of treatment at early stages.
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